Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Abbott gets global rights to Neurocrine's elagolix

Executive Summary

Neurocrine Biosciences Inc. (developing treatments for neurological and endocrine diseases) has licensed Abbott Laboratories Inc. exclusive worldwide rights to develop and commercialize elagolix and next-generation gonadotropin-releasing hormone (GnRH) antagonists for women's and men's health.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies